Glucosamine Sulphate and Ginkgo Biloba as Antifungal Activity for Treating Tinea Pedis
1 other identifier
interventional
30
1 country
1
Brief Summary
Tinea Pedis infected the feet of about 20-25% of the world population. Tinea Pedis is a fungal infection of the feet and it is easily spread. Oral therapy is usually used for chronic conditions or when topical treatment has failed. The aim of this study is to prove the antifungal and antibacterial activity of Ginko Biloba (GKB) \& Glucosamine (GL) as separate material or both in combination.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_1
Started Jan 2016
Longer than P75 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 26, 2015
CompletedStudy Start
First participant enrolled
January 1, 2016
CompletedFirst Posted
Study publicly available on registry
August 29, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2022
CompletedOctober 10, 2019
October 1, 2019
4.7 years
November 26, 2015
October 9, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Assessment the antifungal activity of Ginkgo Biloba & Glucosamine
Ginkgo Biloba and Glucosamine will be applied with infected patients even systemically or topically. The results will be compared with control groups to prove the Antifungal Activity.
six months
Secondary Outcomes (1)
Stability test for different dosage forms
three months
Study Arms (2)
Infected group
ACTIVE COMPARATORA group of volunteers infected with Tinea pedis, Capitis and Versicolor received Ginkgo Biloba in different dosage forms.
Control group
PLACEBO COMPARATORA group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo without Ginkgo Biloba.
Interventions
Eligibility Criteria
You may qualify if:
- It is important to follow up and collect data, preferably for six months for local and systemic activity of Ginkgo Biloba and Glucosamine, to establish whether the infection recurrent or not.
You may not qualify if:
- Larger numbers of participants having different kind of fungal infection are needed to test efficiency drug in order to produce more reliable data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assiut Clinic
Asyut, 71526, Egypt
Related Publications (1)
Tauber A, Muller-Goymann CC. In vitro model of infected stratum corneum for the efficacy evaluation of poloxamer 407-based formulations of ciclopirox olamine against Trichophyton rubrum as well as differential scanning calorimetry and stability studies. Int J Pharm. 2015 Oct 15;494(1):304-11. doi: 10.1016/j.ijpharm.2015.08.023. Epub 2015 Aug 11.
PMID: 26276254RESULT
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- phD and Lectrurer, Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy
Study Record Dates
First Submitted
November 26, 2015
First Posted
August 29, 2016
Study Start
January 1, 2016
Primary Completion
September 1, 2020
Study Completion
October 1, 2022
Last Updated
October 10, 2019
Record last verified: 2019-10